Figure 1.
Overview of the design strategy used in this study.
Table 1.
Demographic and clinical features of the colorectal cancer (CRC) patients and healthy controls.
Table 2.
Primers used for qRT-PCR in this study.
Figure 2.
Different expression levels of six selected miRNAs in the CRC and healthy control serum samples.
The serum expression levels of the six selected miRNAs were measured in 113 CRC cases and 89 healthy control subjects (in both the training set and the validation set) using a SYBR-based qRT-PCR assay. Each reaction was carried out in triplicate.
Table 3.
Differentially expressed miRNAs in CRC serum samples compared with serum samples from the controls in the training and validation sets.
Figure 3.
Sensitivity and specificity of the six-miRNA signature for discriminating between CRC and healthy control samples.
(A) ROC curve analysis for the profile of the six- miRNA signature in the training set yielded an AUC value of 0.900 (95% CI: 0.812–0.988) with 83.3% sensitivity and 96.7% specificity (cut-off value = 9.595). (B) ROC curve analysis for the profile of the six-miRNA signature in the validation set yielded an AUC value of 0.923 (95% CI: 0.869–0.976) with 96.4% sensitivity and 88.1% specificity (cut-off value = 9.595). (C) Carcinoembryonic antigen (CEA) yielded an AUC value of 0.649 (95% CI): 0.574–0.724) with 35.4% sensitivity and 94.4% specificity and (D) carbohydrate antigen 19-9 (CA19-9) yielded an AUC value of 0.598 (95% CI: 0.521–0.676) with 23% sensitivity and 96.6% specificity, for the same serum samples.
Table 4.
Risk score analysis of CRC patients and healthy controls.